C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study

In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-05, Vol.16 (9), p.1725
Hauptverfasser:	Morikawa, Toshiharu, Naiki, Taku, Sugiyama, Yosuke, Naiki-Ito, Aya, Nagai, Takashi, Etani, Toshiki, Iida, Keitaro, Isobe, Teruki, Noda, Yusuke, Shimizu, Nobuhiko, Aoki, Maria, Gonda, Masakazu, Banno, Rika, Kubota, Hiroki, Ando, Ryosuke, Umemoto, Yukihiro, Kawai, Noriyasu, Yasui, Takahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Apoptosis Biomarkers Bladder cancer C-reactive protein Cancer Cancer patients Cancer therapies Carcinoma Care and treatment Cell death Chemotherapy Development and progression Gender Geriatrics Medical prognosis Medical research Medicine, Experimental Metastases Metastasis Multivariate analysis Neuropathy Neutrophils Nutritional status Patients Proteins Pruritus Skin diseases Tumors Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!